OrderlyMeds Stands Firm Against Eli Lilly's Cease-and-Desist Over Compounding Practices
OrderlyMeds' Defiance Against Eli Lilly
In an assertive response to a Cease-and-Desist letter received from Eli Lilly on April 1, 2025, OrderlyMeds has publicly declared its commitment to patient-centered healthcare. The core of the dispute centers around the practice of compounding Tirzepatide, a medication tailored for individual health needs.
OrderlyMeds stands by the tradition of pharmacists and prescribers compounding medications for their patients—something that has been done long before Eli Lilly's existence. This practice allows healthcare providers to address unique medical requirements, ensuring patients receive therapies specifically designed to meet their individual situations. For instance, patients with allergies or those sensitive to specific dosages benefit immensely from customized treatment plans.
Chris Spears, the founder and CEO of OrderlyMeds, emphasized that patients deserve an active role in their healthcare decisions. He states that compounded medications are vital tools in achieving personalized medical regimens that cater specifically to the individual.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.